Literature DB >> 9736576

Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

G G Zhanel1, I D Kirkpatrick, D J Hoban, A M Kabani, J A Karlowsky.   

Abstract

The MICs and MBCs of 15 antibiotics for two strains of Staphylococcus aureus were determined in Mueller-Hinton broth (MHB) and 90% serum-10% MHB. Subsequent experiments established that highly protein-bound antibiotics (>/=80%), such as LY333328, demonstrated higher MICs and MBCs, less killing over an 8-h interval, and shorter postantibiotic effects in 90% serum-10% MHB than in MHB alone. Albumin was demonstrated to be almost solely responsible for changes in the aforementioned pharmacodynamic parameters of LY333328.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736576      PMCID: PMC105846     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

3.  Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.

Authors:  Y W Lam; M H Duroux; J G Gambertoglio; S L Barriere; B J Guglielmo
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

4.  Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

Authors:  C W Stratton; L B Reller
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

5.  Anomalous effect of serum on the antimicrobial activity of cefoperazone.

Authors:  S D Lang; G L Cameron; P R Mullins
Journal:  Drugs       Date:  1981       Impact factor: 9.546

6.  Human serum enhances the postantibiotic effect of fluoroquinolones against Staphylococcus aureus.

Authors:  R J Davidson; G G Zhanel; R Phillips; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

Authors:  H Sun; M S Chow; E G Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

8.  Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli.

Authors:  J E Leggett; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

9.  Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.

Authors:  H F Chambers; J Mills; T A Drake; M A Sande
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec

10.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more
  12 in total

1.  Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Authors:  Florian M E Wagenlehner; Martina Kinzig-Schippers; Uwe Tischmeyer; Christine Wagenlehner; Fritz Sörgel; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

2.  Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors:  G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

4.  Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.

Authors:  E A Coyle; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Assessment of oritavancin serum protein binding across species.

Authors:  Francis F Arhin; Adam Belley; Geoffrey McKay; Sylvain Beaulieu; Ingrid Sarmiento; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

6.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 7.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Impact of human serum albumin on oritavancin in vitro activity against enterococci.

Authors:  Geoffrey A McKay; Sylvain Beaulieu; Ingrid Sarmiento; Francis F Arhin; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

9.  Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.

Authors:  Daniel Gonzalez; Paula Delmore; Barry T Bloom; C Michael Cotten; Brenda B Poindexter; Elisabeth McGowan; Karen Shattuck; Kathleen K Bradford; P Brian Smith; Michael Cohen-Wolkowiez; Maurine Morris; Wanrong Yin; Daniel K Benjamin; Matthew M Laughon
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.938

10.  A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants.

Authors:  Rachel G Greenberg; Huali Wu; Anil Maharaj; Michael Cohen-Wolkowiez; Kay M Tomashek; Blaire L Osborn; Reese H Clark; Emmanuel B Walter
Journal:  Pediatr Infect Dis J       Date:  2020-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.